PL3784285T3 - Środki krioprotekcyjne do formulacji cząstek stałych - Google Patents
Środki krioprotekcyjne do formulacji cząstek stałychInfo
- Publication number
- PL3784285T3 PL3784285T3 PL19718760.2T PL19718760T PL3784285T3 PL 3784285 T3 PL3784285 T3 PL 3784285T3 PL 19718760 T PL19718760 T PL 19718760T PL 3784285 T3 PL3784285 T3 PL 3784285T3
- Authority
- PL
- Poland
- Prior art keywords
- particulate formulations
- cryoprotective agents
- cryoprotective
- agents
- particulate
- Prior art date
Links
- 239000002577 cryoprotective agent Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18169325 | 2018-04-25 | ||
EP18189010 | 2018-08-14 | ||
PCT/EP2019/060646 WO2019207061A1 (en) | 2018-04-25 | 2019-04-25 | Cryoprotective agents for particulate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3784285T3 true PL3784285T3 (pl) | 2023-12-18 |
Family
ID=66240151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL19718760.2T PL3784285T3 (pl) | 2018-04-25 | 2019-04-25 | Środki krioprotekcyjne do formulacji cząstek stałych |
Country Status (13)
Country | Link |
---|---|
US (2) | US20210137840A1 (pl) |
EP (3) | EP3784284B1 (pl) |
JP (2) | JP7256824B2 (pl) |
KR (2) | KR20210021943A (pl) |
CN (2) | CN112153985B (pl) |
AU (2) | AU2019258679A1 (pl) |
BR (2) | BR112020021054A2 (pl) |
CA (2) | CA3098259C (pl) |
ES (2) | ES2960939T3 (pl) |
MX (2) | MX2020011167A (pl) |
PL (1) | PL3784285T3 (pl) |
WO (2) | WO2019207060A1 (pl) |
ZA (1) | ZA202006026B (pl) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102128248B1 (ko) | 2011-06-08 | 2020-07-01 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
DK2718269T3 (en) | 2011-06-08 | 2018-04-09 | Translate Bio Inc | SPLITLY LIPIDS |
EP3620447B1 (en) | 2012-03-29 | 2021-02-17 | Translate Bio, Inc. | Ionizable cationic lipids |
DK2968586T3 (en) | 2013-03-14 | 2018-10-08 | Translate Bio Inc | CFTR MRNA COMPOSITIONS AND RELATED PROCEDURES AND APPLICATIONS |
AU2014239264A1 (en) | 2013-03-14 | 2015-08-27 | Shire Human Genetic Therapies, Inc. | Quantitative assessment for cap efficiency of messenger RNA |
BR112016008832A2 (pt) | 2013-10-22 | 2017-10-03 | Shire Human Genetic Therapies | Distribuição de mrna no snc e suas utilizações |
EA201690576A1 (ru) | 2013-10-22 | 2016-10-31 | Шир Хьюман Дженетик Терапис, Инк. | Липидные композиции для доставки матричной рнк |
EP3587409B8 (en) | 2014-05-30 | 2022-07-13 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
EP3226912B1 (en) | 2014-12-05 | 2021-01-20 | Translate Bio, Inc. | Messenger rna therapy for treatment of articular disease |
IL266501B2 (en) | 2016-11-10 | 2024-06-01 | Translate Bio Inc | An improved ICE-based lipid nanoparticle formulation for delivery of mRNA |
US10808241B2 (en) | 2017-02-27 | 2020-10-20 | Translate Bio, Inc. | Methods for purification of messenger RNA |
WO2018231709A1 (en) | 2017-06-12 | 2018-12-20 | Translate Bio, Inc. | Poly(phosphoesters) for delivery of nucleic acids |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
CN112153985B (zh) * | 2018-04-25 | 2024-03-01 | 埃泽瑞斯公司 | 用于颗粒制剂的防冻剂 |
CA3100218A1 (en) | 2018-05-16 | 2019-11-21 | Translate Bio, Inc. | Ribose cationic lipids |
CN112424214A (zh) | 2018-05-30 | 2021-02-26 | 川斯勒佰尔公司 | 包含甾族部分的阳离子脂质 |
WO2020035460A1 (en) * | 2018-08-14 | 2020-02-20 | Ethris Gmbh | Lipid-based formulations containing salts for the delivery of rna |
AU2019325702A1 (en) | 2018-08-24 | 2021-02-25 | Translate Bio, Inc. | Methods for purification of messenger RNA |
US20220087935A1 (en) | 2019-01-07 | 2022-03-24 | Translate Bio, Inc. | Composition and Methods for Treatment of Primary Ciliary Dyskinesia |
US11453877B2 (en) | 2019-05-15 | 2022-09-27 | Translate Bio, Inc. | Methods for purification of messenger RNA |
CN114599676A (zh) | 2019-10-24 | 2022-06-07 | 诺华康制药股份公司 | 新型抗-Nogo-A抗体 |
AU2021226578A1 (en) | 2020-02-25 | 2022-10-20 | Translate Bio, Inc. | Improved processes of preparing mRNA-loaded lipid nanoparticles |
US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
EP0826063A1 (en) * | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
CN100462066C (zh) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
TW520294B (en) | 1998-01-08 | 2003-02-11 | Res Dev Foundation | Stabilization of lipid: DNA formulations during nebulization |
EP1766053A4 (en) * | 2004-06-02 | 2007-12-12 | Sourcepharm Inc | MICROVESICLES CONTAINING RNA AND METHODS |
CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
EP4332227A1 (en) | 2005-08-23 | 2024-03-06 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
ES2564241T3 (es) | 2005-12-02 | 2016-03-21 | Glaxosmithkline Biologicals Sa | Nanopartículas para su uso en composiciones inmunogénicas |
CN101370817B (zh) | 2005-12-15 | 2012-08-08 | 国立科学研究中心 | 阳离子寡核苷酸、制备阳离子寡核苷酸的自动化方法及其用途 |
EP2902013A1 (en) * | 2008-10-16 | 2015-08-05 | Marina Biotech, Inc. | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics |
CN104910025B (zh) | 2008-11-07 | 2019-07-16 | 麻省理工学院 | 氨基醇类脂质和其用途 |
WO2011012316A2 (de) | 2009-07-31 | 2011-02-03 | Ludwig-Maximilians-Universität | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
EP2509636B1 (en) | 2009-12-07 | 2017-07-19 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
AU2012255194B2 (en) * | 2011-05-16 | 2017-01-05 | Danmarks Tekniske Universitet | Charge triggering of self-organized nanoparticles |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
GB201118704D0 (en) * | 2011-10-28 | 2011-12-14 | Univ Oxford | Cystic fibrosis treatment |
KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
DK2858677T3 (da) | 2012-06-08 | 2020-08-31 | Ethris Gmbh | Pulmonær levering af messenger rna |
EP3757570B1 (en) * | 2013-03-15 | 2023-10-11 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
DK3013964T3 (da) | 2013-06-28 | 2020-06-15 | Ethris Gmbh | Sammensætninger til indføring af rna i celler |
CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
RU2016138020A (ru) * | 2014-02-26 | 2018-03-29 | Этрис Гмбх | Композиции для введения phk в желудочно-кишечный тракт |
DK3221293T3 (da) | 2014-11-18 | 2023-04-03 | Arcturus Therapeutics Inc | Ioniserbar kationisk lipid til RNA-afgivelse |
EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
EP3247363A4 (en) * | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
CN112153985B (zh) * | 2018-04-25 | 2024-03-01 | 埃泽瑞斯公司 | 用于颗粒制剂的防冻剂 |
-
2019
- 2019-04-25 CN CN201980034447.1A patent/CN112153985B/zh active Active
- 2019-04-25 JP JP2020559465A patent/JP7256824B2/ja active Active
- 2019-04-25 KR KR1020207030471A patent/KR20210021943A/ko unknown
- 2019-04-25 BR BR112020021054-4A patent/BR112020021054A2/pt unknown
- 2019-04-25 EP EP19718759.4A patent/EP3784284B1/en active Active
- 2019-04-25 JP JP2020558887A patent/JP2021522228A/ja active Pending
- 2019-04-25 WO PCT/EP2019/060644 patent/WO2019207060A1/en unknown
- 2019-04-25 AU AU2019258679A patent/AU2019258679A1/en active Pending
- 2019-04-25 US US17/050,441 patent/US20210137840A1/en active Pending
- 2019-04-25 WO PCT/EP2019/060646 patent/WO2019207061A1/en unknown
- 2019-04-25 US US17/050,440 patent/US20210137846A1/en active Pending
- 2019-04-25 AU AU2019258678A patent/AU2019258678A1/en active Pending
- 2019-04-25 MX MX2020011167A patent/MX2020011167A/es unknown
- 2019-04-25 EP EP23187109.6A patent/EP4311541A3/en active Pending
- 2019-04-25 KR KR1020207030470A patent/KR20210022535A/ko unknown
- 2019-04-25 ES ES19718760T patent/ES2960939T3/es active Active
- 2019-04-25 CA CA3098259A patent/CA3098259C/en active Active
- 2019-04-25 PL PL19718760.2T patent/PL3784285T3/pl unknown
- 2019-04-25 BR BR112020021037-4A patent/BR112020021037A2/pt unknown
- 2019-04-25 MX MX2020011166A patent/MX2020011166A/es unknown
- 2019-04-25 CA CA3098262A patent/CA3098262A1/en active Pending
- 2019-04-25 EP EP19718760.2A patent/EP3784285B1/en active Active
- 2019-04-25 ES ES19718759T patent/ES2960936T3/es active Active
- 2019-04-25 CN CN201980034487.6A patent/CN112153986B/zh active Active
-
2020
- 2020-09-29 ZA ZA2020/06026A patent/ZA202006026B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3784285C0 (en) | CRYOPROTECTING AGENTS FOR PARTICULAR FORMULATIONS | |
IL273416A (en) | A long-term external parasiticide agent for animals | |
IL277079A (en) | Cartirin preparations and methods of use | |
GB2590821B (en) | Freely-transformable multipurpose carrier | |
GB201814169D0 (en) | Blockchain autonoumous agents | |
GB201814281D0 (en) | Cytotoxic agents | |
IL286100A (en) | Formulations of anti-il-36r antibodies | |
IL281976A (en) | Formulations of anti-FGFR2 antibody | |
IL291131A (en) | Formulations of anti-il-23p19 antibodies | |
GB201809976D0 (en) | Novel formulations | |
EP3658590C0 (de) | Photoinitiatoren für lichthärtende zusammensetzungen | |
IL283886A (en) | Antibody Formulations | |
PT4045038T (pt) | Novas formulações de 4-cloro-n-[2-[(4-clorofenil)metil]-3-oxo-1,2,4-tiadiazol-5-il]benzamida | |
CA185969S (en) | Particulate spreader | |
SG11202008431UA (en) | Catalyst formulations | |
IL282515A (en) | Preparations and methods for improving sperm function | |
GB2594907B (en) | Composition comprising anti-acanthamoeba agents | |
SG11202010097WA (en) | Apixaban formulations | |
CA196729S (en) | Horseshoe | |
SG11202011823SA (en) | Activator-nucleator formulations | |
GB201819028D0 (en) | Butanol-based formulations | |
GB201808386D0 (en) | Formulations | |
GB201804545D0 (en) | Formulations | |
GB201803201D0 (en) | Formulations | |
ZA202103578B (en) | Dna-cutting agent |